Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).

XAU/USD consolidates above the 50-day MA, as softer U.S. data boosts rate cut odds. Gold price future hinges on inflation and ...

Trump has said that tariffs on pharmaceutical imports could reach 250%, the steepest rate he has proposed for the sector. Trump, who in July threatened 200% duties, wants to motivate drug companies to ...

Billions are lost to crypto fraud annually. Learn how the top cryptocurrency scams work and how to protect your capital from ...

The issuer is solely responsible for the content of this announcement.